Investigational drug · Phase 2
RL-007
Also called: Inidascamine
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "RL-007"
First trial start
2022
Dec 8, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RL-007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cognitive Impairment Associated With Schizophrenia (CIAS)
- Cognitive Impairment
- Schizophrenia
Approved drugs for the same conditions: Schizophrenia · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "RL-007" as an intervention, largest first.
- A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)Pivotal-lookingCompleted
Recognify Life SciencesIndustry
NCT05686239 · 242 participants · Start Dec 8, 2022 · Primary completion Apr 9, 2025
Drug: RL-007 (Inidascamine); Placebo · For: Cognitive Impairment Associated With Schizophrenia (CIAS); Cognitive Impairment; Schizophrenia
Sites: Culver City, California; Garden Grove, California; Lafayette, California · 36 sites in all
Recognify Life SciencesIndustry
NCT04822883 · 37 participants · Start Apr 26, 2021 · Primary completion Oct 28, 2021
Drug: RL-007; RL-007 Matching Placebo · For: Cognitive Impairment; Schizophrenia
Sites: Long Beach, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cognitive Impairment Associated With Schizophrenia (CIAS)
- KYN-5356Phase 21 trial
Kynexis B.V. · Cognitive Impairment Associated With Schizophrenia (CIAS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.